News >

Larotrectinib Inches Closer to FDA Approval for TRK+ Cancers

Angelica Welch
Published: Monday, May 21, 2018

Anna F. Farago, MD, PhD

Anna F. Farago, MD, PhD
Loxo Oncology completed a rolling new drug application (NDA) to the FDA in March 2018 for larotrectinib (LOXO-101), a pan-TRK inhibitor codeveloped by Bayer. If approved, larotrectinib would be available as a treatment for both adult and pediatric patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion.

in patients with locally advanced solid tumors.

OncLive: Can you provide some background on larotrectinib?

Farago: There have been 3 trials with this drug. There was a phase I study with adult patients, a phase I/II trial for pediatric patients, and a phase II study for adolescents and adults. Those data were put together for a presentation at the 2017 ASCO Annual Meeting, and then in a recent publication in the New England Journal of Medicine. We participated in the phase I adult study and in the phase II adolescent and adult study. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication